[ad_1]
Hamilton, ON (June 9, 2019) – A clinical trial followed by more than 9,900 people in 24 countries found that the drug, dulaglutide, was reducing cardiovascular events and kidney problems in people of average age and over older people with type 2 diabetes.
For more than five years of follow-up, cardiovascular events such as heart attacks and strokes were reduced by 12% in people taking dulaglutide compared to those taking placebo. This effect has been observed in men and women with and without previous cardiovascular disease.
In addition, during the same period, the drug reduced the development of renal failure by 15%.
The study was led by the Institute of Population Health Research (PHRI) of McMaster University and Hamilton Health Sciences. Two articles describing the cardiovascular and renal results of the test were published today in the review The lancet of the study called Cardiovascular Events Research with a weekly test of Incretin in Diabetes (REWIND).
"Compared to other people with diabetes, the number of cardiovascular events such as heart attacks and strokes is twice as high, and up to 40% of people with diabetes develop an illness kidney, "said Hertzel C. Gerstein, principal investigator of the study, professor of medicine. at McMaster and Deputy Director of PHRI.
"The REWIND trial shows that dulaglutide can safely reduce these events, while improving diabetes control and slightly reducing weight and blood pressure in middle-aged people with type 2 diabetes." 2. "
Nearly one in five people over the age of 60 has diabetes and most of them have type 2 diabetes. In total, almost ten percent of adults live with diabetes , including 425 million worldwide. 100 million in the United States and three million in Canada.
Dulaglutide is a glucagon-like peptide 1 receptor agonist that is injected once a week. It is approved for the reduction of blood sugar and helps the pancreas release the right amount of insulin when blood glucose is high, slows stomach emptying after a meal and reduces appetite and weight.
Gerstein pointed out that the participants in the trial were very similar to the types of people with diabetes encountered in medical practice. Participants were followed for a median of 5.4 years, much longer than previous trials, and more than 46% of participants were women. Less than a third of participants had previous cardiovascular disease.
The drug was well tolerated, exhibited a slightly reduced weight, low density lipoprotein (LDL) related cholesterol and blood pressure, as well as a modest increase in heart rate. Gastrointestinal adverse events, including constipation and diarrhea, were reported more frequently in participants taking dulaglutide (47%) compared with placebo (34%).
###
The REWIND trial was funded by Eli Lilly and Company, manufacturer of the drug Dulaglutide Trulicity. The study was designed and led by a team of scientists composed of representatives of the funder. The data was badyzed by PHRI scientists and the principal investigator was ultimately responsible for the articles.
Publishers:
Video clips: https: /
Photos: https: /
Photo Caption: Dr. Hertzel Gerstein is a Professor of Medicine and Endocrinologist at McMaster University and Hamilton Health Sciences. Photo courtesy of Hamilton Health Sciences.
Warning: AAAS and EurekAlert! are not responsible for the accuracy of the news releases published on EurekAlert! contributing institutions or for the use of any information via the EurekAlert system.
Source link
